英矽智能报考港股上市，2025年2月完成超1亿美元E轮融资

Core Viewpoint - InSilico Medicine is pursuing an IPO on the Hong Kong Stock Exchange, having submitted updated prospectus documents after previous attempts in June 2023 and March 2024 [1][3]. Group 1: Company Overview - InSilico Medicine, established in June 2019, has a registered capital of $56 million and is fully owned by InSilico Medicine Hong Kong Limited [5]. - The company is an AI-driven biotechnology firm with a clinical asset currently in Phase II trials and has generated over 20 clinical or IND-stage assets through its Pharma.AI platform [7]. Group 2: Financial Performance - Revenue for InSilico Medicine was approximately $30.15 million in 2022, $51.18 million in 2023, and is projected to reach $85.83 million in 2024, indicating continuous growth [8]. - The company reported net losses of approximately $222 million in 2022, $212 million in 2023, and $17 million in 2024, showing a significant reduction in losses over the years [8][9]. - Cumulative losses from 2022 to 2024 amount to $440 million, with adjusted net losses (excluding IPO-related expenses) of approximately $70.8 million, $74.7 million, and $11.35 million for the respective years [8]. Group 3: Recent Developments - In March 2023, InSilico Medicine completed a $110 million Series E funding round, which will be used to enhance its proprietary AI models and expand its automated laboratory capabilities [3]. - The company’s post-money valuation after the Series E funding is approximately $1.33 billion [3].